F-Star Therapeutics Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
39
- Latest Deal Type
-
M&A
- (Announced)
- Investors
-
1
F-Star Therapeutics General Information
Description
Developer of tetravalent bispecific antibodies and immunotherapies designed to support immune modulation in cancer treatment. The company offers patent-protected antibody platforms with dual-targeting capability, enabling individuals with cancer to receive extended treatment benefits and improved disease management.
Contact Information
Website
www.f-star.com(Operating Subsidiary)
Corporate Office
- Botanic House, 100 Hills Road
- Cambridgeshire
- Cambridge CB2 1PH
- England, United Kingdom
Corporate Office
- Botanic House, 100 Hills Road
- Cambridgeshire
- Cambridge CB2 1PH
- England, United Kingdom
F-Star Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 02-Apr-2025 | Announced | Clinical Trials - General | |||
| 13. Merger/Acquisition | 08-Mar-2023 | Completed | Clinical Trials - General | |||
| 12. Debt Repayment | 01-Mar-2022 | Completed | Clinical Trials - General | |||
| 11. Reverse Merger | 20-Nov-2020 | Completed | Clinical Trials - General | |||
| 10. Merger/Acquisition | 28-Oct-2014 | Cancelled | Clinical Trials - General | |||
| 9. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 8. Later Stage VC | Completed | Clinical Trials - General | ||||
| 7. Later Stage VC | 23-Oct-2013 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC | 13-Apr-2011 | $21.3M | $49.7M | Completed | Clinical Trials - General | |
| 5. Later Stage VC (Series A) | 06-Jan-2010 | $24.5M | $28.4M | Completed | Startup |
F-Star Therapeutics Comparisons
Industry
Financing
Details
F-Star Therapeutics Competitors (47)
One of F-Star Therapeutics’s 47 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Memo Therapeutics | Formerly VC-backed | Zurich, Switzerland | ||||
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands |
F-Star Therapeutics Patents
F-Star Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260152558-A1 | Multispecific anti-tcr delta variable 1 antibodies | Pending | 27-Nov-2024 | ||
| WO-2026115036-A1 | Multispecific anti-tcr delta variable 1 antibodies | Pending | 27-Nov-2024 | ||
| GB-202304278-D0 | Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy | Inactive | 23-Mar-2023 | ||
| CA-3208653-A1 | Multispecific anti-tcr delta variable 1 antibodies | Pending | 17-Feb-2022 | ||
| WO-2023156604-A1 | Multispecific anti-tcr delta variable 1 antibodies | Inactive | 17-Feb-2022 | C07K16/2803 |
F-Star Therapeutics Signals
F-Star Therapeutics Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aescap Life Sciences | Mutual Fund | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| INiTS Universitäres Gründerservice | Accelerator/Incubator | Minority | ||
| M Ventures | Corporate Venture Capital | Minority | ||
| MP Healthcare Venture Management | Corporate Venture Capital | Minority |
F-Star Therapeutics Acquisitions (1)
F-Star Therapeutics’s most recent deal was a Merger/Acquisition with Spring Bank Pharmaceuticals. The deal was made on 20-Nov-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Spring Bank Pharmaceuticals | 20-Nov-2024 | Merger/Acquisition | Drug Discovery |
F-Star Therapeutics FAQs
-
When was F-Star Therapeutics founded?
F-Star Therapeutics was founded in 2002.
-
Where is F-Star Therapeutics headquartered?
F-Star Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of F-Star Therapeutics?
F-Star Therapeutics has 39 total employees.
-
What industry is F-Star Therapeutics in?
F-Star Therapeutics’s primary industry is Drug Discovery.
-
Is F-Star Therapeutics a private or public company?
F-Star Therapeutics is a Private company.
-
What is F-Star Therapeutics’s current revenue?
The current revenue for F-Star Therapeutics is .
-
How much funding has F-Star Therapeutics raised over time?
F-Star Therapeutics has raised $57.5M.
-
Who are F-Star Therapeutics’s investors?
Aescap Life Sciences, Atlas Venture, INiTS Universitäres Gründerservice, M Ventures, and MP Healthcare Venture Management are 5 of 11 investors who have invested in F-Star Therapeutics.
-
Who are F-Star Therapeutics’s competitors?
Crinetics Pharmaceuticals, Memo Therapeutics, Light Chain Bioscience, Adaptimmune Therapeutics, and Cristal Therapeutics are some of the 47 competitors of F-Star Therapeutics.
-
When was F-Star Therapeutics acquired?
F-Star Therapeutics was acquired on 02-Apr-2025.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process